Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew W Nelson

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
The Journal of Clinical Psychiatry|January 24, 2006
Galantamine-induced QTc prolongationMatthew W Nelson, Robert W Buchanan
Clinical Neuropharmacology|December 4, 2003
Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidoneMatthew W Nelson, Rhonda R Reynolds, Deanna L Kelly, et al.
The Journal of Clinical Psychiatry|January 12, 2005
Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patientDavid S Arnold, Richard B Rosse, Dwight Dickinson, et al.
Schizophrenia Research|February 19, 2008
Quetiapine at high doses for the treatment of refractory schizophreniaDouglas L Boggs, Deanna L Kelly, Stephanie Feldman, et al.
Orphanet Journal of Rare Diseases|December 21, 2021
A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithmJohn L Jefferies, Alison K Spencer, Heather A Lau, et al.
Clinical Neuropharmacology|August 3, 2005
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophreniaRobert R Conley, Deanna L Kelly, Matthew W Nelson, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
The Journal of Clinical Psychiatry|January 24, 2006
Galantamine-induced QTc prolongationMatthew W Nelson, Robert W Buchanan
Clinical Neuropharmacology|December 4, 2003
Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidoneMatthew W Nelson, Rhonda R Reynolds, Deanna L Kelly, et al.
The Journal of Clinical Psychiatry|January 12, 2005
Adjuvant therapeutic effects of galantamine on apathy in a schizophrenia patientDavid S Arnold, Richard B Rosse, Dwight Dickinson, et al.
Schizophrenia Research|February 19, 2008
Quetiapine at high doses for the treatment of refractory schizophreniaDouglas L Boggs, Deanna L Kelly, Stephanie Feldman, et al.
Orphanet Journal of Rare Diseases|December 21, 2021
A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithmJohn L Jefferies, Alison K Spencer, Heather A Lau, et al.
Clinical Neuropharmacology|August 3, 2005
Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophreniaRobert R Conley, Deanna L Kelly, Matthew W Nelson, et al.
Pageof 1